An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
Lancet (London, England)（2022）
摘要
Kyowa Kirin.
更多查看译文
关键词
antibody,moderate-to-severe,double-blind,placebo-controlled
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要